Toward a better liver graft allocation that accounts for candidates with and without hepatocellular carcinoma

American Journal of Transplantation

Volumn 14, Issue 10, 2014, Pages 2221-2227

  Toso, C ^a   Mazzaferro, V ^b   Bruix, J ^c   Freeman, R ^d   Mentha, G ^a   Majno, P ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF BARCELONA   (Spain)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Cancer; clinical research; hepatology; liver disease: malignant; liver transplantation; malignancy; neoplasia; organ procurement and allocation; practice

Indexed keywords

ALPHA FETOPROTEIN;

CANCER SIZE; END STAGE LIVER DISEASE; GRAFT RECIPIENT; HEALTH CARE POLICY; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; MORTALITY; REVIEW; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; HEALTH CARE ORGANIZATION; LIVER NEOPLASMS; PATIENT DROPOUTS;

CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; HEALTH CARE RATIONING; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; PATIENT DROPOUTS;

EID: 84908192200     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12923     Document Type: Review

References (41)

1. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC., A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-871.
2. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-96.
3. Freeman RB, Wiesner RH, Edwards E, Harper A, Merion R, Wolfe R., Results of the first year of the new liver allocation plan. Liver Transpl 2004; 10: 7-15.
4. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
5. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403.
6. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM., Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009; 49: 832-838.
7. Wald C, Russo MW, Heimbach JK, Hussain HK, Pomfret EA, Bruix J., New OPTN/UNOS policy for liver transplant allocation: Standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 2013; 266: 376-382.
8. Cejas NG, Villamil FG, Lendoire JC, et al. Improved waiting-list outcomes in Argentina after the adoption of a model for end-stage liver disease-based liver allocation policy. Liver Transpl 2013; 19: 711-720.
9. Pestana RC, Baracat EI, Massarollo PC, Pereira LA, Szutan LA., Consequences of the implementation of the Model for End-stage Liver Disease system for liver allocation in Brazil. Transplant Proc 2013; 45: 2111-2114.
10. Wong RJ, Devaki P, Nguyen L, Cheung R, Cho-Phan C, Nguyen MH., Increased long-term survival among patients with hepatocellular carcinoma after implementation of model for end-stage liver disease score. Clin Gastroenterol Hepatol 2014; 12: 1534-1540.e1.
11. Goldberg D, French B, Abt P, Feng S, Cameron AM., Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma. Liver Transpl 2012; 18: 434-443.
12. Toso C, Dupuis-Lozeron E, Majno P, et al. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list. Hepatology 2012; 56: 149-156.
13. Washburn K, Edwards E, Harper A, Freeman R., Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant 2010; 10: 1643-1648.
14. Toso C, Majno P, Berney T, Morel P, Mentha G, Combescure C., Validation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting list. Transplant Int 2014; 27: 686-695.
15. Schuetz C, Dong N, Smoot E, et al. HCC patients suffer less from geographic differences in organ availability. Am J Transplant 2013; 13: 2989-2995.
16. Navasa M, Bruix J., Multifaceted perspective of the waiting list for liver transplantation: The value of pharmacokinetic models. Hepatology 2010; 51: 12-15.
17. Freeman RB, Edwards EB, Harper AM., Waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transplant 2006; 6: 1416-1421.
18. Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY., Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: Implications for the current organ allocation policy. Liver Transpl 2013; 19: 1343-1353.
19. Zhu K, Dai Z, Zhou J., Biomarkers for hepatocellular carcinoma: Progression in early diagnosis, prognosis, and personalized therapy. Biomark Res 2013; 1: 10.
20. Giordano S, Columbano A., MicroRNAs: New tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology 2013; 57: 840-847.
21. Scaggiante B, Kazemi M, Pozzato G, et al. Novel hepatocellular carcinoma molecules with prognostic, therapeutic potentials. World J Gastroenterol 2014; 20: 1268-1288.
22. Toso C, Mentha G, Majno P., Liver transplantation for hepatocellular carcinoma: Five steps to prevent recurrence. Am J Transplant 2011; 11: 2031-2035.
23. Toso C, Mentha G, Kneteman NM, Majno P., The place of downstaging for hepatocellular carcinoma. J Hepatol 2010; 52: 930-936.
24. Merani S, Majno P, Kneteman NM, et al. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol 2011; 55: 814-819.
25. Piscaglia F, Camaggi V, Ravaioli M, et al. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system. Liver Transpl 2007; 13: 857-866.
26. Cucchetti A, Cescon M, Bertuzzo V, et al. Can the dropout risk of candidates with hepatocellular carcinoma predict survival after liver transplantation? Am J Transplant 2011; 11: 1696-1704.
27. Huo TI, Huang YH, Su CW, et al. Validation of the HCC-MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy. Clin Transplant 2008; 22: 469-475.
28. Cucchetti A, Cescon M, Bigonzi E, et al. Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy. Liver Transpl 2011; 17: 1344-1354.
29. Cescon M, Cucchetti A, Ravaioli M, Pinna AD., Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J Hepatol 2013; 58: 609-618.
30. Pomfret EA, Washburn K, Wald C, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010; 16: 262-278.
31. Roberts JP, Venook A, Kerlan R, Yao F., Hepatocellular carcinoma: Ablate and wait versus rapid transplantation. Liver Transpl 2010; 16: 925-929.
32. Ravaioli M, Grazi GL, Dazzi A, et al. Survival benefit after liver transplantation: A single European center experience. Transplantation 2009; 88: 826-834.
33. Schaubel DE, Sima CS, Goodrich NP, Feng S, Merion RM., The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008; 8: 419-425.
34. Schaubel DE, Guidinger MK, Biggins SW, et al. Survival benefit-based deceased-donor liver allocation. Am J Transplant 2009; 9 (4 Pt 2): 970-981.
35. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA., The survival benefit of liver transplantation. Am J Transplant 2005; 5: 307-313.
36. Cillo U, Vitale A, Volk ML, et al. The survival benefit of liver transplantation in hepatocellular carcinoma patients. Dig Liver Dis 2010; 42: 642-649.
37. Vitale A, Morales RR, Zanus G, et al. Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: A multicentre, cohort study. Lancet Oncol 2011; 12: 654-662.
38. Vitale A, Volk ML, De Feo TM, et al. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. J Hepatol 2013; 60: 290-297.
39. Kadry Z, Schaefer EW, Uemura T, Shah AR, Schreibman I, Riley TR III., Impact of geographic disparity on liver allocation for hepatocellular cancer in the United States. J Hepatol 2012; 56: 618-625.
40. EASL-EORTC. EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
41. Wiesner RH, Freeman RB, Mulligan DC., Liver transplantation for hepatocellular cancer: The impact of the MELD allocation policy. Gastroenterology 2004; 127 (5 Suppl 1): S261-S267.